Efficacy, duration, and absorption of a paediatric oral liquid preparation of ranitidine hydrochloride.
The objectives of this study were to assess the clinical efficacy of a new oral ranitidine liquid preparation in reducing gastric acidity and volume, to determine the degree of absorption of the drug, and to determine the duration of drug effect. Eighty preoperative children between the ages of one and six years were enrolled in each of three centres. Each subject was allocated to one of the following groups: Group A - apple juice, 5 ml.kg-1 plus placebo liquid; Group B - apple juice, 5 ml.kg-1 plus ranitidine hydrochloride 2 mg.kg-1; Group C - water, 5 ml and placebo liquid; or Group D - water, 5 ml and ranitidine liquid 2 mg.kg-1. All study agents were administered at least two hours before surgery along with a dye marker, sulfobromophthalein 1 ml (50 mg.ml-1). Following induction of anaesthesia, gastric fluid was aspirated, and analyzed for pH, volume, and sulfobromophthalein content (as an index of the ingested fluids). A serum sample was also drawn and analyzed for ranitidine content by high performance liquid chromatography. Groups B and D had fewer subjects with pH below 2.5 and gastric volume > 0.4 ml.kg-1. The duration of reduced volume and acidity was shown to be greatest from two to four hours after drug administration. Thirty-three percent of subjects receiving oral ranitidine, 2 mg.kg-1 hydrochloride as a single dose demonstrated no measurable effect on gastric pH and volume; 28 of those subjects had adequate ranitidine serum levels.
Goresky
G V
GV
Department of Anaesthesia, Alberta Children's Hospital, Calgary.
Finley
G A
GA
Bissonnette
B
B
Shaffer
E A
EA
D000042:Absorption; D000284:Administration, Oral; D001628:Beverages; D002648:Child; D002675:Child, Preschool; D005215:Fasting; D005638:Fruit; D005744:Gastric Acid / Q000737:chemistry / Q000378:metabolism*; D005745:Gastric Acidity Determination; D005766:Gastrointestinal Contents / Q000737:chemistry / Q000187:drug effects*; D006801:Humans; D007223:Infant; D010919:Placebos; D011015:Pneumonia, Aspiration / Q000517:prevention & control; D011899:Ranitidine / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016037:Single-Blind Method; D013448:Sulfobromophthalein; D013997:Time Factors; D014867:Water
D010919:Placebos; D014867:Water; D013448:Sulfobromophthalein; D011899:Ranitidine